Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PODOMOUNT-Basket
NL-OMON61146Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apecotrep in proteinuric kidney disease, focal segmental glomerulosclerosis (FSGS), nephrosis, Alport syndrome, membranous glomerulonephritis (MGN), sponsored by Boehringer Ingelheim. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
apecotrep
03
Conditions
proteinuric kidney diseasefocal segmental glomerulosclerosis (FSGS)nephrosisAlport syndromemembranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on NL-OMON61146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61146.